Applied DNA Executes LOI with Spindle Biotech for Research Collaboration on Simplified High Yield mRNA Production System

Applied DNA Executes LOI with Spindle Biotech for Research Collaboration on Simplified High Yield mRNA Production System
CANNANNEW REPORT

– Companies Aim to Bring Together LinearDNA™ and Spindle Biotech’s Proprietary Engineered RNA Polymerase to Develop a Next-Generation, Cell-Free mRNA Production Platform – STONY BROOK, N.Y. & TORONTO–(BUSINESS WIRE)–$APDN #LinearDNA—Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in cell-free, enzymatic DNA production, and Spindle Biotech Inc. (“Spindle Biotech”), a company focused on the development of a novel, high yield, and low-cost RNA production systems, today announced that the two companies have executed a non-binding letter of intent (“LOI”) that outlines the terms of a collaborative research agreement (the “Definitive Agreement”) to investigate the feasibility of utilizing the Company’s LinearDNATM platform to produce chemically modified DNA templates for use in Spindle Biotech’s proprietary, high yield RNA manufacturing system. The companies believe the combination of their respective platforms provides for a simplified, high yield, and 100% cell-free workflow that is differentiated from current mRNA production that uses plasmid DNA (pDNA). In addition to increased speed and purity, the use of LinearDNA as an IVT template for mRNA production removes several complex manufacturing steps necessitated by pDNA. The companies believe that Spindle Biotech’s proprietary, high yield, and engineered RNA polymerase, which requires a chemically modified DNA template, is particularly well suited to leverage the unique advantages of Applied DNA’s PCR-based LinearDNA platform. Under the proposed Definitive Agreement terms, Applied DNA will produce specialized IVT DNA templates for RNA transcription using Spindle Biotech’s RNA polymerase. Following initial validation work, the companies intend to explore the commercialization of an mRNA production system that leverages the benefits of the companies’ respective platforms. Dr. James A. Hayward, president and CEO of Applied DNA, stated, “We believe that Spindle’s mRNA manufacturing approach is a very good fit for our LinearDNA platform, which excels at the efficient production of chemically modified DNA constructs. As demand for mRNA…

Excerpt only …
READ MORE BELOW
Source : Applied DNA Executes LOI with Spindle Biotech for Research Collaboration on Simplified High Yield mRNA Production System

reposted by Cannabis News World

This site uses Akismet to reduce spam. Learn how your comment data is processed.